EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023

Jessie R Chung iD, Philip Shirk, Manjusha Gaglani, Manohar B Mutnal, Mary Patricia Nowalk iD, Krissy Moehling Geffel, Stacey L House, Tara Curley, Karen J Wernli, Erika L Kiniry, Emily T Martin iD, Ivana A Vaughn iD und 12 weitere

Influenza and Other Respiratory Viruses · 2024-06 · 18 (6)

DOI: 10.1111/irv.13342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 23.06.2024. Verfasst von Jessie R Chung und 23 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Influenza A Virus, H3N2 Subtype, Influenza A Virus, H1N1 Subtype. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Centers for Disease Control and Prevention Cooperative Agreement, NCIRD CDC HHS, ACL HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2022–23 US influenza season peaked early in fall 2022.

Methods

Late‐season influenza vaccine effectiveness (VE) against outpatient, laboratory‐confirmed influenza was calculated among participants of the US Influenza VE Network using a test‐negative design.

Results

Of 2561 participants enrolled from December 12, 2022 to April 30, 2023, 91 laboratory‐confirmed influenza cases primarily had A(H1N1)pdm09 (6B.1A.5a.2a.1) or A(H3N2) (3C.2a1b.2a.2b). Overall, VE was 30% (95% confidence interval −9%, 54%); low late‐season activity precluded estimation for most subgroups.

Conclusions

2022–23 late‐season outpatient influenza VE was not statistically significant. Genomic characterization may improve the identification of influenza viruses that circulate postinfluenza peak.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H1N1 SubtypeOutpatientsSeasonsVaccine EfficacyHumansAdultMaleFemaleUnited StatesMiddle AgedYoung AdultAdolescentAgedChildChild, PreschoolInfantVaccinationAged, 80 and over

Stichwörter der Autor:innen

influenzavaccinationvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Baylor Scott & White Health, Temple, Texas, USA.
  • Department of Pediatrics, Baylor College of Medicine, Temple, Texas, USA.
  • Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Emergency Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
  • Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.

ORCID-Profile: Jessie R Chung, Mary Patricia Nowalk, Emily T Martin, Ivana A Vaughn, Vel Murugan

Förderung

  • US Centers for Disease Control and Prevention Cooperative Agreement
  • NCIRD CDC HHS
  • ACL HHS
  • NCI NIH HHS
  • NIH HHS
  • NCATS NIH HHS
  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Chung, J. R., Shirk, P., Gaglani, M., Mutnal, M. B., Nowalk, M. P., Moehling Geffel, K., House, S. L., Curley, T., Wernli, K. J., Kiniry, E. L., Martin, E. T., Vaughn, I. A., Murugan, V., Lim, E. S., Saade, E., Faryar, K., Williams, O. L., Walter, E. B., Price, A. M., …, & Flannery, B. (2024). Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023. Influenza and Other Respiratory Viruses, 18(6). https://doi.org/10.1111/irv.13342

Vancouver

Chung JR, Shirk P, Gaglani M, Mutnal MB, Nowalk MP, Moehling Geffel K, et al. Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023. Influenza and Other Respiratory Viruses. 2024;18(6). doi:10.1111/irv.13342

BibTeX
@article{Chung2024,
  author = {Chung, Jessie R and Shirk, Philip and Gaglani, Manjusha and Mutnal, Manohar B and Nowalk, Mary Patricia and Moehling Geffel, Krissy and House, Stacey L and Curley, Tara and Wernli, Karen J and Kiniry, Erika L and Martin, Emily T and Vaughn, Ivana A and Murugan, Vel and Lim, Efrem S and Saade, Elie and Faryar, Kiran and Williams, Olivia L and Walter, Emmanuel B and Price, Ashley M and Barnes, John R and DaSilva, Juliana and Kondor, Rebecca and Ellington, Sascha and Flannery, Brendan},
  title = {Late‐Season Influenza Vaccine Effectiveness Against Medically Attended Outpatient Illness, United States, December 2022–April 2023},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  volume = {18},
  number = {6},
  doi = {10.1111/irv.13342}
}
Kostenlos starten →